Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12052757 | 1.00 | L3MBTL1 (0.48) | L3MBTL1ADAM17MDM4TP53MDM2 | |
| SCHEMBL29353403 | 0.93 | ADAM17 (0.51) | L3MBTL1ADAM17MDM4TP53MDM2 | |
| SCHEMBL30917941 | 0.93 | ADAM17 (0.51) | L3MBTL1ADAM17MDM4TP53MDM2 | |
| SCHEMBL5969202 | 0.93 | ADAM17 (0.51) | L3MBTL1ADAM17MDM4TP53MDM2 | |
| SCHEMBL1709188 | 0.93 | ADAM17 (0.51) | L3MBTL1ADAM17MDM4TP53MDM2 | |
| SCHEMBL29364320 | 0.93 | ADAM17 (0.51) | L3MBTL1ADAM17MDM4TP53MDM2 | |
| SCHEMBL1000833 | 0.93 | ADAM17 (0.51) | L3MBTL1ADAM17MDM4TP53MDM2 | |
| SCHEMBL30645044 | 0.93 | TACR1 (0.48) | L3MBTL1ADAM17MDM4TP53MDM2 | |
| SCHEMBL16289392 | 0.92 | L3MBTL1 (0.47) | L3MBTL1ADAM17MDM4TP53MDM2 | |
| SCHEMBL16289393 | 0.92 | L3MBTL1 (0.47) | L3MBTL1ADAM17MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735441-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7691852-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20070293465-A1 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293465-A1 | Compounds for enzyme inhibition | PSME1, PSMB1, PSME3 | L3MBTL1 1290/4885ADAM17 464/4885MDM4 1727/4885 |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | L3MBTL1 1290/4885ADAM17 464/4885MDM4 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.